Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation

References

• Horsman MR, Overgaard J. Hyperthermia: A potent enhancer of radiotherapy. Clin Oncol 2007;19:418–26
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487–97
   PubMed Web of Science ®Google Scholar
• Franckena M. Review of radiotherapy and hyperthermia in primary cervical cancer. Int J Hyperthermia 2012;28:543–8
   PubMed Web of Science ®Google Scholar
• Oleson JR. Hyperthermia from the clinic to the laboratory: A hypothesis. Int J Hyperthermia 1995;11:315–22
   PubMed Web of Science ®Google Scholar
• Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006;22:197–203
   PubMed Web of Science ®Google Scholar
• Vaupel PW, Kelleher DK. Blood flow and associated pathophysiology of uterine cervix cancers: Characterisation and relevance for localised hyperthermia. Int J Hyperthermia 2012;28:518–27
   PubMed Web of Science ®Google Scholar
• Meng Q, He C, Shuaib A, Wang CX. Hyperthermia worsens ischaemic brain injury through destruction of microvessels in an embolic model in rats. Int J Hyperthermia 2012;28:24–32
   PubMed Web of Science ®Google Scholar
• Jain RK, Grantham FH, Gullino PM. Blood flow and heat transfer in Walker 256 mammary carcinoma. J Natl Cancer Inst 1979;62:927–33
   PubMed Web of Science ®Google Scholar
• Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 1979;5:235–41
   PubMed Web of Science ®Google Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977;123:511–14
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979;39:966–72
   PubMed Web of Science ®Google Scholar
• Thrall DE, Gillette EL, Dewey WC. Effect of heat and ionizing radiation on normal and neoplastic tissue of the C3H mouse. Radiat Res 1975;63:363–77
   PubMed Web of Science ®Google Scholar
• Dewey WC, Thrall DE, Gillette EL. Hyperthermia and radiation – A selective thermal effect on chronically hypoxic tumor cells in vivo. Int J Radiat Oncol Biol Phys 1977;2:99–103
   PubMed Web of Science ®Google Scholar
• Wallen CA, Colby TV, Stewart JR. Cell kill and tumor control after heat treatment with and without vascular occlusion in RIF-1 tumors. Radiat Res 1986;106:215–23
   PubMed Web of Science ®Google Scholar
• Urano M, Montoya V, Booth A. Effect of hyperglycemia on the thermal response of murine normal and tumor tissue. Cancer Res 1983;43:453–5
   PubMed Web of Science ®Google Scholar
• Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989;5:123–36
   PubMed Web of Science ®Google Scholar
• Prescott DM, Samulski TV, Dewhirst MW, Page RL, Thrall DE, Dodge RK, et al. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 1992;23:377–85
   PubMed Web of Science ®Google Scholar
• Yano T, Tanase M, Watanabe A, Sawada H, Yamada Y, Shino Y, et al. Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res 1995;15:1355–8
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Murata R, Hiraoka M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996;73:270–4
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjorkhaug ST, Dahl O. Hyperthermia exhibits anti-vascular activity in the BT4An rat glioma: Lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia 2002;18:141–52
   PubMed Web of Science ®Google Scholar
• Verhulst J. Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia 2013;29:62–70
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. In: Sugahara T, Saito M, editors. Hyperthermic Oncology, Vol. 1. London: Taylor & Francis; 1989. pp 258–9
   Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996;12:335–44
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000;2:555–60
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 2003;19:575–89
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal and radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518–23
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting therapies and hyperthermia. In: Siemann DW, editor. Vascular-Targeted Therapies in Oncology. Chichester: Wiley; 2006. pp 137–57
   Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Vascular targeting agents: Adjuvants to radiation therapy. Radiother Oncol 2000;57:5–12
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520–39
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res 2009;335:241–8
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001;40:497–503
   PubMed Web of Science ®Google Scholar
• Murata R, Horsman MR. Tumour specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004;20:393–404
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1018–24
   PubMed Web of Science ®Google Scholar
• Hokland S, Horsman MR. The new vascular disrupting agent combretastatin A-1 disodium phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitisation. Int J Hyperthermia 2007;23:599–606
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Williams BW, Koonce NA, Bischof JC, Song CW, Asur R, et al. Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors. J Oncol 2012. doi: 10.1155/2012/934918
   PubMedGoogle Scholar
• Clémenson C, Chargari C, Deutsch E. Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol Hematol 2013;86:143–60
   PubMed Web of Science ®Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12:4090–4
   PubMed Web of Science ®Google Scholar
• Folkes LK, Christlieb M, Madej E, Stratford MRL, Wardman P. Oxidative metabolism of combretastatin A-1 produces quinine intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 2007;20:1885–94
   PubMed Web of Science ®Google Scholar
• Overgaard K, Overgaard J. Investigations on the possibility of a thermic tumour therapy – 1. Short-wave treatment of a transplanted isologous mouse mammary carcinoma. Eur J Cancer 1972;8:65–78
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980;6:1507–15
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stødkilde-Jørgensen H, et al. Combretastatins: Novel vascular targeting drugs for improving anti-cancer therapy. Adv Exp Med Biol 2000;476:311–23
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047–55
   PubMed Web of Science ®Google Scholar
• Horsman MR, Chaplin DJ, Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells. Cancer Res 1990;50:7430–6
   PubMed Web of Science ®Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization: Mode of action and clinical relevance. Int J Radiat Biol 2001;77:399–408
   PubMed Web of Science ®Google Scholar
• Roti Roti JL. Introduction: Radiosensitization by hyperthermia. Int J Hyperthermia 2004;20:109–14
   PubMed Web of Science ®Google Scholar
• Moulder JE, Rockwell S. Hypoxic fractions of solid tumors. Int J Radiat Biol Oncol Phys 1984;10:695–712
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: A review. Cancer Res 1989;49:6449–65
   PubMed Web of Science ®Google Scholar
• Hendry JH. Quantitation of the radiotherapeutic importance of naturally-hypoxic normal tissues from collated experiments with rodents using single doses. Int J Radiat Oncol Biol Phys 1979;5:971–6
   PubMed Web of Science ®Google Scholar
• Iversen AB, Busk M, Horsman MR. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol 2013;52:1320–6
   PubMed Web of Science ®Google Scholar
• Masunaga S-I, Liu Y, Sakurai Y, Tanaka H, Suzuki M, Kondo N, et al. Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential. Int J Hyperthermia 2012;28:636–44
   PubMed Web of Science ®Google Scholar